Image Place holder

Farhad Khimani, MD


Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Khimani’s Clinical interest is specifically in Blood and Marrow transplantation. His area of focus is Lymphoma and Acute Leukemia.  He routinely takes care of patients with Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, Acute Myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome etc. who require autologous or allogeneic hematopoietic stem cell transplantation as a curative treatment option for their malignancy.

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology

Fellowship:

  • West Virginia University - Hematology/Oncology
  • Moffitt Cancer Center - Blood and Marrow Transplantation

Residency:

  • West Virginia University - Internal Medicine

Medical School:

  • Aga Khan University Medical College - MD
Participating Trials

CLINICAL TRIAL 18814
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Condition: Malignant Hematology
Intervention: busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18664
A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T cell Non-Hodgkin's Lymphoma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Carmustine; Cytarabine (Cytosine Arabinoside); FK228 (Romidepsin); Melphalan; Romidepsin; etoposide
Open

CLINICAL TRIAL 18964
Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
Condition: Malignant Hematology
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Placebo
Open

CLINICAL TRIAL 19143
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease
Condition: Malignant Hematology
Intervention: ATG; Alkeran (Melphalan); FK506 (Tacrolimus); MESNA; Melphalan; Tacrolimus; busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate
Open

CLINICAL TRIAL 17263
Phase I Trial of ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Tacrolimus
Open

CLINICAL TRIAL 17676
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention:
Open

CLINICAL TRIAL 17967
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: KTE-C19; Levetiracetam; Tocilizumab; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18331
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Condition: Malignant Hematology
Intervention:
Open

CLINICAL TRIAL 18430
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: Panobinostat (LBH589)
Open

CLINICAL TRIAL 18816
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Malignant Hematology
Intervention: Atezolizumab (Tecentriq); KTE-C19; Not Applicable; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18374
A Phase II Trial Evaluating the use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Condition: Malignant Hematology
Intervention: Not Applicable; Panobinostat (LBH589)
Open

CLINICAL TRIAL 17790
A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Marrow Infiltrating Lymphocytes (MILs); Melphalan; Tadalafil
Open

CLINICAL TRIAL 18217
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Bortezomib; FK506 (Tacrolimus); Ixazomib (Ninlaro); Melphalan; Not Applicable; PS-341 (Bortezomib); Placebo; Tacrolimus; Velcade (Bortezomib); fludarabine (Fludarabine phosphate); methotrexate
Open

CLINICAL TRIAL 18766
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); Mycophenolate Mofetil; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18763
A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; prednisone
Open

CLINICAL TRIAL 18783
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); FK506 (Tacrolimus); Melphalan; Pacritinib; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Tacrolimus; busulfan; fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18950
A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 18626
Carfilzomib for Treatment of Chronic Graft vs. Host Disease
Condition: Malignant Hematology
Intervention: carfilzomib (Kyprolis)
Open

CLINICAL TRIAL 19089
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)
Condition: Malignant Hematology
Intervention: Thymoglobulin; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19119
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: Jakafi (Ruxolitinib); Methylprednisolone; Ruxolitinib; prednisone
Open

CLINICAL TRIAL 19070
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May;102(5):948-957. Pubmedid: 28104702. Pmcid: PMC5477614.
  • Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec;22(12):2201-2207. Pubmedid: 27660169.
  • Khimani F, Curley B, Almubarak M. Survey of Patients Referred to a University Cancer Center for Benign Hematology: Quality Measures and Patient Understanding. J Oncol Pract. 2015 Jan;11(1):26-29. Pubmedid: 25406129.
  • Khimani F, Hoban C, Williams V, Mavromatis B, Auber ML, Abraham J, Higa GM. Efficacy of solubilized vemurafenib administered via nasogastric tube. Future Oncol. 2014 Feb;10(2):165-170. Pubmedid: 24490602.
  • Palla AR, Khimani F, Craig MD. Warm Autoimmune Hemolytic Anemia with a Direct Antiglobulin Test Positive for C3 and Negative for IgG: A Case Study and Analytical Literature Review of Incidence and Severity. Clin Med Insights Case Rep. 2013 May;6:57-60. Pubmedid: 23645992. Pmcid: PMC3623608.
  • Kamal A, Khimani F, Raza R, Zafar S, Bandeali S, Jan S. Characteristics of TIA and its management in a tertiary care hospital in Pakistan. BMC Res Notes. 2008 Aug;1:73. Pubmedid: 18755043. Pmcid: PMC2546420.
  • Majeed K, Mahmud H, Khawaja HR, Mansoor S, Masood S, Khimani F. Complementary and Alternative Medicine: Perceptions of Medical Students from Pakistan. Med Educ Online. 2007 Dec;12(1):4469. Pubmedid: 28253096.